A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment December 15, 2017 Type of Cancer Myelodysplastic Syndrome Sponsor Janssen Protocol Number 63935937MDS3001 To Learn More Call (201)-510-0950
